STUDY COMPARING THE COMBINED USE OF AVONEX AND COPAXONE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是确定使用干扰素β 1a（Avonex）和醋酸格拉替雷（Copaxone）治疗复发性多发性硬化症（RRMS）是否安全，可耐受和有效，而不是单独使用一种药物。Avonex的标准剂量是每周一次肌肉注射30 mcg。Copaxone的标准剂量为每日皮下给药20 mg。这两种治疗方法，Avonex和Copaxone都是食品和药物批准的药物。然而，在其标准剂量下的联合使用未经FDA批准。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether it is safe,tolerable and effective to use both interferone beta 1a (Avonex) and glatiramer acetate (Copaxone) for the treatment of relapsing multiple sclerosis (RRMS), rather than using only one agent alone. The standard dose for Avonex is 30 mcg administered once a week into the muscle. The standard dose of Copaxone is 20 mg administered daily under the skin. Both, treatments, Avonex and Copaxone are Food and Drug approved drugs. However, the combined use at their standard doses is not FDA approved.